protein
fold
complex
errorpron
process
often
result
irrepar
protein
byproduct
byproduct
recogn
cellular
qualiti
control
machineri
target
proteasomedepend
degrad
fold
protein
secretori
pathway
add
anoth
layer
protein
fold
problem
endoplasm
reticulum
maintain
uniqu
chemic
environ
within
cell
fact
grow
number
diseas
attribut
defect
secretori
protein
fold
mani
byproduct
target
process
known
endoplasm
reticulumassoci
degrad
erad
sinc
discoveri
research
mechan
underli
erad
pathway
provid
new
insight
erad
contribut
human
health
normal
diseas
state
link
erad
diseas
evidenc
loss
protein
function
result
degrad
chronic
cellular
stress
erad
fail
keep
misfold
protein
product
abil
pathogen
coopt
erad
pathway
grow
number
erad
substrat
also
illumin
differ
machineri
use
recogn
degrad
vast
array
potenti
client
pathway
despit
known
erad
mani
question
remain
new
paradigm
like
emerg
clearli
key
success
diseas
treatment
lie
within
defin
molecular
detail
erad
pathway
understand
conserv
pathway
select
degrad
innumer
cast
substrat
thought
protein
fold
follow
direct
pathway
dictat
sum
interact
form
amino
acid
includ
ion
pair
van
der
waal
forc
hydrophob
interact
hydrogen
bond
howev
decad
biophys
comput
research
yield
sophist
view
protein
fold
instead
nonlinear
process
protein
navig
number
differ
energi
landscap
may
adopt
funnellik
shape
lowest
energi
fold
state
bottom
funnel
fold
inform
mainli
present
amino
acid
side
chain
involv
local
distant
interact
driven
larg
need
isol
hydrophob
residu
within
protein
core
howev
even
view
may
naiv
protein
fold
must
occur
complex
highli
crowd
environ
estim
reach
concentr
high
mgml
cytoplasm
thu
intramolecular
interact
imping
effici
protein
fold
cell
prevent
illegitim
interand
intramolecular
interact
protect
hydrophob
amino
acid
side
chain
emerg
ribosom
fold
aid
class
protein
known
molecular
chaperon
base
propens
bind
short
peptid
hydrophob
charact
molecular
chaperon
guard
misfold
aggreg
case
molecular
chaperon
increas
rate
fold
rather
increas
number
product
interact
prevent
misguid
interact
thu
augment
fold
effici
heat
shock
protein
hsp
kda
repres
three
import
class
chaperon
substratebind
pocket
low
atpas
activ
stimul
interact
cochaperon
partner
contain
amino
acid
motif
known
jdomain
highli
conserv
critic
protein
fold
protein
transloc
protein
degrad
assembl
disassembl
protein
complex
also
bind
substrat
via
interact
thought
handoff
substrat
enhanc
basal
atpas
activ
adpbound
state
exhibit
higher
affin
peptid
substrat
transfer
substrat
result
tight
complex
ultim
member
divers
class
nucleotid
exchang
factor
help
releas
adp
turn
free
peptid
substrat
thu
complex
help
control
maintain
solubl
protein
may
otherwis
aggreg
interact
substrat
mediat
one
domain
dimer
chaperon
case
relationship
atp
hydrolysi
substrat
bind
releas
complex
nucleotidefre
state
may
import
intermedi
chaperon
cycl
gener
accept
though
usual
function
later
step
protein
fold
pathway
given
complex
protein
fold
difficult
imagin
one
mani
problem
may
aris
exampl
nascent
polypeptid
may
aggreg
due
unwant
interact
amongst
hydrophob
amino
acid
side
chain
estim
mani
onethird
newli
synthes
protein
may
degrad
cell
type
presum
due
problem
synthesi
fold
protein
misfold
aggreg
actual
quit
common
respons
number
human
patholog
alzheim
diseas
huntington
diseas
parkinson
diseas
defici
protein
aggreg
lead
format
amyloid
deposit
tissu
throughout
bodi
even
though
protein
result
amyloid
fibril
product
quit
vari
fibril
share
mani
gener
structur
featur
suggest
common
fate
amongst
mani
aggreg
product
howev
propens
given
polypeptid
form
amyloid
highli
sensit
cellular
environ
see
exampl
ref
nearli
onethird
newli
synthes
protein
target
er
first
step
deliveri
protein
traffick
organel
secretori
pathway
extracellular
space
nascent
secret
protein
emerg
ribosom
exit
tunnel
present
nh
termin
hydrophob
signal
sequenc
aqueou
environ
cytoplasm
signal
sequenc
follow
strict
consensu
gener
residu
length
contain
common
featur
basic
motif
hydrophob
core
short
polar
region
emerg
signal
sequenc
captur
ribonucleoprotein
complex
known
signal
recognit
particl
srp
consist
six
protein
singl
rna
one
srp
subunit
bind
gtp
requir
particl
function
srp
two
gener
role
translat
arrest
provid
window
opportun
ribosomenasc
chain
complex
find
er
membran
target
releas
nascent
peptid
er
membran
transloc
complex
see
fig
er
membran
srp
associ
heterodimer
srp
receptor
stimul
srp
hydrolysi
gtp
srp
releas
ribosomenasc
chain
complex
translat
resum
result
insert
nascent
peptid
transloc
pore
translocon
protein
transloc
occur
complex
mammalian
cell
three
subunit
complex
alpha
beta
gamma
provid
aqueou
pore
protein
insert
either
er
lumen
hydrophob
membranespan
segment
encount
directli
lipid
bilay
er
fig
b
insert
membranespan
domain
thought
occur
open
translocon
later
movement
hydrophob
environ
membran
sever
studi
indic
translocon
quit
flexibl
may
accommod
multipl
transmembran
helici
insert
polytop
membran
protein
transloc
hydrophob
signal
sequenc
cleav
signal
sequenc
peptidas
complex
intim
associ
er
membran
upon
insert
er
space
transloc
protein
also
interact
chaperon
promot
fold
undergo
cotransl
modif
discuss
protein
target
transloc
origin
thought
highli
effici
evid
contrari
given
fact
signal
sequenc
quit
divers
surpris
sometim
interchang
toler
certain
alter
see
exampl
ref
howev
signal
sequenc
divers
known
import
target
transloc
signal
sequenc
cleavag
effici
exampl
signal
sequenc
er
lectin
calreticulin
somewhat
ineffici
result
cytosol
popul
chaperon
addit
abund
er
pool
chimer
protein
contain
signal
sequenc
calreticulin
prolactin
anoth
wellcharacter
secretori
protein
use
demonstr
ineffici
transloc
chimera
contain
calreticulin
signal
sequenc
vitro
vivo
addit
use
transloc
report
append
onto
varieti
signal
sequenc
suggest
protein
normal
enter
secretori
pathway
ineffici
target
insert
er
whether
repres
need
retain
cytosol
pool
secret
protein
inher
ineffici
target
system
complet
clear
signal
sequenc
ineffici
propos
underli
mechan
pathophysiolog
neurodegen
condit
caus
prion
protein
prp
glycoprotein
unknown
function
resid
cell
surfac
prion
diseas
sporad
genet
infecti
result
accumul
misfold
prp
fatal
neurodegener
prp
synthesi
protein
cotransl
insert
er
modifi
glycophosphatidylinositol
anchor
initi
tether
prp
er
membran
ultim
cellular
plasma
membran
examin
biogenesi
diseasecaus
mutat
prp
suggest
prp
pathogenesi
result
ineffici
matur
er
follow
retrotransloc
aggreg
cytosol
howev
subsequ
studi
indic
cytoplasm
accumul
prp
due
retrotransloc
instead
ineffici
prp
signal
sequenc
result
format
either
cytoplasm
cy
prp
form
transmembran
ctm
prp
form
protein
note
ctm
prp
accumul
stabl
speci
express
correl
neurodegener
mice
human
consist
data
diseasecaus
mutat
result
accumul
ctm
prp
rescu
increas
effici
signal
sequenc
insert
result
highlight
sensit
protein
homeostasi
diseas
subtl
differ
protein
synthesi
target
andor
transloc
effici
support
view
silent
mutat
multidrug
resist
transport
simpli
chang
protein
translat
rate
leav
amino
acid
sequenc
unchang
alter
transport
substrat
specif
coincid
transloc
nascent
protein
encount
er
uniqu
environ
contrast
sharpli
organel
chemic
properti
protein
composit
chemic
er
oxid
calciumrich
oxid
potenti
favor
format
disulfid
bond
calcium
serv
necessari
cofactor
mani
chaperon
vital
cellular
signal
addit
er
pack
protein
aid
fold
protein
catalyz
erspecif
posttransl
modif
form
protein
qualiti
control
machineri
uniqu
posttransl
modif
also
occur
er
signal
sequenc
cleavag
transloc
protein
may
modifi
sugar
moieti
specif
asn
side
chain
via
process
known
nlink
glycosyl
note
may
acquir
disulfid
bond
modif
contribut
protein
nativ
fold
disulfid
bond
form
oxid
pair
free
thiol
cystein
residu
disulfid
bond
help
stabil
protein
may
especi
import
protein
secret
harsh
extracellular
milieu
lysosom
acid
sometim
disulfid
bond
serv
link
proteolyt
cleav
subunit
cholera
toxin
insulin
see
help
maintain
stabil
oligomer
secret
protein
immunoglobulin
incorrect
acquisit
mainten
disulfid
bond
give
rise
form
clot
diseas
von
willebrand
diseas
connect
tissu
disord
marfan
diseas
enzym
catalyz
format
disulfid
bond
gener
refer
protein
disulfid
isomeras
pdi
pdi
also
function
isomer
disulfid
bond
mammalian
er
contain
differ
pdi
famili
member
character
presenc
one
thioredoxinlik
domain
protein
fold
disulfid
bond
form
incorrectli
form
bond
must
broken
therefor
cycl
pdi
action
vital
protein
fold
famili
first
name
pdi
first
protein
shown
abil
form
disulfid
bond
er
protein
interestingli
pdi
possess
oxidoreductas
activ
well
chaperonelik
activ
essenti
foldingsecret
mani
protein
includ
procollagen
trimer
er
calcium
concentr
rang
stark
contrast
cytoplasm
calcium
concentr
nm
ref
er
calcium
releas
mediat
inositol
receptor
ip
r
open
upon
bind
second
messeng
ip
plasma
membran
excit
variou
signal
protein
includ
hormon
growth
factor
neurotransmitt
result
phospholipas
cmediat
cleavag
plasma
membran
phospholipid
gener
ip
wave
releas
calcium
critic
numer
cellular
event
muscl
contract
exocytosi
cell
prolifer
immun
respons
transcript
activ
apoptosi
note
follow
activ
certain
signal
ip
r
level
downregul
erad
mechan
attenu
respons
ip
signal
releas
calcium
reconcentr
sarcoendoplasm
reticulum
ca
atpas
serca
coupl
free
energi
atp
hydrolysi
pump
calcium
concentr
gradient
back
er
mani
er
chaperon
includ
pdi
bip
also
known
er
lumen
homolog
calnexin
calreticulin
see
bind
calcium
thought
help
buffer
calcium
level
addit
role
protein
fold
import
er
calcium
becam
even
evid
discov
disturb
er
calcium
store
alter
secret
sever
protein
surpris
mani
diseas
includ
spinocerebellar
ataxia
heart
diseas
darier
diseas
directli
link
defect
ip
receptor
serca
function
introduc
anoth
posttransl
modif
occur
er
protein
transloc
addit
sugar
moieti
guid
consensu
signal
asnxserthr
sugar
transfer
asn
side
chain
thu
event
term
nlink
glycosyl
nglycan
protect
protein
stabil
protein
structur
interact
mediat
interact
qualiti
control
lectin
er
calnexin
calreticulin
also
see
therefor
nlink
glycan
intim
involv
earli
protein
fold
event
larg
number
diseas
also
link
improp
glycosyl
secret
protein
current
known
genet
diseas
aris
either
improp
assembl
process
nglycan
collect
known
congenit
disord
glycosyl
exampl
individu
mutat
encod
glucosyltransferas
hyptonia
strabism
seizur
low
circul
level
certain
glycoprotein
includ
coagul
inhibitor
protein
c
antithrombin
acquir
nglycan
compos
two
nacetylglucosamin
nine
mannos
three
glucos
moieti
transfer
oligosaccharyltranferas
complex
ogt
en
bloc
precursor
asn
side
chain
follow
enzymat
cleavag
remov
two
three
glucos
residu
nascent
glycoprotein
interact
lectinlik
chaperon
calnexin
calreticulin
protein
interact
calnexin
calreticulin
maintain
cleavag
final
glucos
residu
follow
decis
fold
statu
must
made
still
unfold
glycoprotein
rebind
calnexincalreticulin
reglucosyl
udpglucos
glycoprotein
glycosyltransferas
give
protein
time
attain
fold
conform
howev
protein
fail
fold
soon
enough
stochast
remov
mannos
residu
er
mannosidas
trigger
select
misfold
protein
degrad
erad
pathway
particularli
import
player
event
er
degrad
enhanc
protein
propos
interact
specif
glycan
conform
produc
glycan
trim
repeat
fold
cycl
andor
function
timer
degrad
trim
mannos
glycoprotein
substrat
commit
degrad
howev
recent
studi
challeng
view
demonstr
interact
misfold
substrat
regardless
glycosy
state
reconcil
two
contrast
view
provid
observ
low
express
erad
misfold
version
asialoglycoprotein
receptor
requir
glycan
trim
wherea
high
express
mannos
trim
requir
furthermor
overexpress
stimul
erad
nonglycosyl
version
suggest
dual
role
perhap
regul
cellular
level
addit
diseas
aris
directli
defect
nlink
glycosyl
import
glycosyl
human
health
diseas
underscor
fact
cellular
stress
result
defect
protein
glycosyl
experiment
best
evidenc
fact
tunicamycin
fungal
metabolit
prevent
nglycosyl
inhibit
earli
step
assembl
glycan
chain
treatment
tunicamycin
result
buildup
misfold
glycoprotein
within
er
induct
unfold
protein
respons
upr
diseas
divers
diabet
neurodegener
heart
kidney
diseas
cancer
link
upr
induct
least
case
diseas
progress
aris
fact
prolong
upr
activ
trigger
apoptosi
discuss
preced
section
mani
problem
occur
protein
target
er
subsequ
fold
event
protein
misfold
detriment
result
loss
nativ
protein
function
lead
toxic
gain
function
due
aggreg
misfold
protein
er
also
induc
upr
fortun
cell
evolv
two
main
strategi
clear
unwant
protein
secretori
pathway
erad
main
focu
review
autophagi
beyond
scope
articl
discuss
briefli
subsequ
section
degrad
process
fail
effect
remov
misfold
aberr
protein
er
upr
induct
becom
critic
maintain
cellular
homeostasi
upr
conserv
cellular
stress
respons
trigger
activ
three
signal
transduct
pathway
net
effect
upr
activ
gener
translat
repress
coupl
expans
er
fold
degrad
capac
first
hint
upr
exist
aros
observ
variou
stress
condit
includ
glucos
starvat
inhibit
glycosyl
treatment
mammalian
cell
calcium
ionophor
increas
express
two
erloc
chaperon
bip
data
studi
indic
presenc
unfold
protein
er
primari
trigger
respons
identif
stress
respons
element
promot
yeast
bip
homolog
subsequ
genet
approach
led
identif
conserv
erloc
kinas
inositolrequir
protein
ref
er
stress
activ
initi
cleavag
intron
messag
encod
transcript
factor
yeast
mammal
remov
translat
inhibitori
region
protein
product
activ
transcript
gene
encod
chaperon
enzym
requir
er
protein
fold
factor
requir
erad
lipid
biosynthet
enzym
enlarg
er
compon
augment
ertogolgi
protein
traffick
subsequ
work
indic
mammalian
upr
includ
action
two
addit
er
compon
perk
respect
activ
downstream
respons
inhibit
protein
synthesi
activ
stressrespons
proapoptot
gene
two
model
propos
describ
unfold
protein
activ
branch
upr
first
interact
bip
er
lumin
particip
protein
fold
degrad
process
interact
may
act
sensor
er
protein
fold
statu
accumul
misfold
protein
would
titrat
bip
away
therebi
allow
dimer
phosphoryl
activ
ribonucleas
domain
splice
activ
support
model
demonstr
diffus
bip
within
er
lumen
invers
correl
level
misfold
protein
er
second
model
directli
bind
misfold
protein
via
peptidebind
pocket
data
base
crystal
structur
yeast
fact
mutat
peptidebind
pocket
compromis
upr
induct
suggest
upr
activ
directli
misfold
protein
howev
less
obviou
whether
mammalian
homolog
also
accommod
unfold
polypeptid
end
like
upr
activ
proce
via
combin
two
model
inde
evid
bip
modul
upr
effici
local
signal
durat
sever
upr
target
gene
encod
protein
facilit
erad
principl
provid
rapid
direct
mean
clear
er
potenti
toxic
protein
gener
erad
broken
four
step
substrat
recognit
ubiquitin
retrotransloc
cytosol
proteasomemedi
degrad
addit
clear
misfold
protein
er
due
cell
stress
degrad
protein
mutat
misfold
erad
pathway
also
use
regul
level
specif
enzym
lipid
carrier
includ
hmgcoa
reductas
catalyz
ratedetermin
step
cholesterol
biosynthesi
apolipoprotein
b
requir
assembl
cholesterolcontain
liposom
defect
metabolicallyregul
destruct
er
resid
lead
varieti
diseas
link
lipid
homeostasi
atherosclerosi
reason
erad
vital
human
health
increas
evid
link
pathway
mani
diseas
tabl
embark
discuss
select
eradassoci
diseas
begin
discuss
key
find
defin
erad
pathway
sinc
discoveri
also
provid
overview
step
describ
key
player
pathway
highlight
remain
section
review
earli
studi
assembl
tcell
receptor
tcr
first
hint
exist
known
erad
klausner
colleagu
discov
unassembl
alpha
beta
delta
subunit
heptamer
tcr
degrad
nonlysosom
compart
hypothes
degrad
either
occur
erresid
proteas
anoth
prelysosom
compart
evid
pregolgi
degrad
came
studi
examin
mammalian
protein
includ
subunit
asialoglycoprotein
receptor
hmgcoa
reductas
unassembl
immunoglobulin
light
chain
cytochrom
addit
report
use
mammalian
cell
system
parallel
work
bud
yeast
saccharomyc
cerevisia
also
hint
exist
novel
lysosomeindepend
degrad
pathway
exampl
transloc
defect
elicit
temperaturesensit
mutant
translocon
compon
found
rescu
delet
gene
encod
ubiquitinconjug
enzym
integr
yeast
er
membran
data
suggest
role
cytoplasm
proteasom
turnov
misfold
er
membran
protein
ie
mutant
soon
proteasomedepend
degrad
immatur
wildtyp
mutant
form
cystic
fibrosi
transmembran
conduct
regul
cftr
report
mammalian
cell
also
see
sect
iia
requir
deliveri
aberr
solubl
protein
er
cytoplasm
emerg
studi
misfold
yeast
secretori
protein
proalpha
factor
cpi
use
vitro
genet
tool
protein
found
retrotransloc
er
destroy
proteasom
retrotransloc
degrad
solubl
protein
mammalian
er
also
observ
ultim
quickli
becam
clear
erad
core
requir
underli
mechan
pathway
conserv
yeast
human
erad
begin
recognit
misfold
protein
molecular
chaperon
fig
erad
substrat
present
misfold
lesion
either
er
lumen
er
membran
cytoplasm
influenc
type
chaperon
interact
bip
introduc
er
lumin
discov
virtu
stabl
bind
immunoglobulin
ig
heavi
chain
see
bind
bip
newli
synthes
protein
occur
expos
hydrophob
surfac
client
protein
event
obscur
aggregationpron
surfac
protein
attempt
attain
nativ
fold
state
howev
fold
delay
protein
termin
misfold
extend
chaperon
interact
may
serv
one
two
function
prolong
prevent
aggreg
mainten
unfold
substrat
andor
elabor
process
misfold
protein
shuttl
chaperon
andor
erad
machineri
evid
second
function
came
studi
demonstr
bip
bound
ig
light
chain
ig
bip
associ
reduc
oxid
form
ig
wherea
bound
primarili
oxid
form
suggest
chaperon
interact
ig
sequenti
fashion
bip
also
bound
tightli
nonsecret
form
ig
evid
first
function
came
studi
examin
degrad
solubl
yeast
substrat
yeast
temperaturesensit
allel
gene
encod
bip
substrat
aggreg
high
temperatur
phenomenon
observ
cochaperon
partner
mutat
togeth
studi
highlight
chaperon
work
togeth
differ
stage
protein
foldingdegrad
nglycan
bind
chaperonelik
lectin
er
play
essenti
role
protein
fold
erad
funnel
glucosetrim
glycoprotein
calnexincalreticulin
fold
cycl
govern
ogt
competit
exit
cycl
degrad
discuss
exit
cycl
trigger
action
er
mannosidas
mammalian
cell
ermani
isozym
trim
mannos
residu
specif
branch
glycan
structur
prevent
reglucosyl
simultan
promot
substrat
retrotransloc
degrad
expect
modul
er
mannosidas
level
direct
effect
effici
degrad
specif
substrat
mutant
form
protein
caus
antitrypsin
defici
see
sect
iie
interestingli
yeast
homolog
complex
pdi
similar
interact
observ
mammalian
cell
er
oxidoreductas
observ
may
indic
substrat
select
link
acquisit
protein
proper
disulfid
bond
accord
view
pdi
homolog
also
associ
calnexin
protein
ubiquitin
critic
target
substrat
proteasom
ubiquitin
chain
usual
attach
onto
ly
residu
misfold
protein
although
recent
data
indic
erad
substrat
contain
ubiquitin
chain
ser
thr
residu
protein
ubiquitin
occur
via
threestep
process
mediat
ubiquitinactiv
enzym
ubiquitinconjug
enzym
ubiquitin
ligas
catalyz
final
transfer
ubiquitin
substrat
thought
ligas
provid
substrat
specif
accordingli
abund
three
class
put
ligas
identifi
mammalian
cell
key
involv
erad
chip
basi
chemic
structur
divers
erad
substrat
like
addit
contribut
pathway
emerg
initi
ubiquitin
attach
ubiquitin
chain
extens
polyubiquitin
occur
coval
modif
addit
ubiquitin
monom
onto
ly
residu
previous
link
ubiquitin
form
extend
isopeptidelink
polyubiquitin
chain
case
cooper
extens
polyubiquitin
chain
mediat
anoth
group
enzym
augment
erad
effici
chain
four
ubiquitin
must
append
onto
substrat
effici
proteasom
interact
polyubiquitin
chain
distinguish
base
residu
upon
chain
built
word
type
linkag
determin
fate
ubiquitin
substrat
initi
polyubiquitin
chain
built
upon
isopeptid
linkag
assum
specif
proteasom
degrad
wherea
polyubiquitin
chain
serv
nonproteasom
signal
endocytosi
dna
repair
howev
proteom
studi
reveal
sever
ubiquitin
linkag
exist
cell
chain
append
onto
erad
substrat
futur
research
continu
unravel
function
differ
linkag
mix
linkag
exist
nevertheless
clear
protein
extend
polyubiquitin
chain
found
intracellular
inclus
neurodegen
diseas
suggest
ineffici
proteasom
degrad
link
diseas
phenotyp
see
section
iib
polyubiquitin
erad
substrat
must
deliv
retrotransloc
proteasom
exist
ident
retrotransloc
channel
er
membran
remain
contest
sever
put
channel
consid
includ
transloc
channel
derlin
famili
polytop
membran
protein
intim
link
erad
substrat
compon
erad
machineri
polytop
ubiquitin
ligas
use
retrotransloc
channel
initi
seem
logic
yeast
found
mutant
prevent
erad
substrat
erad
substrat
form
disulfid
bond
cy
residu
en
rout
degrad
result
suggest
protein
unfold
retrotransloc
anoth
erad
substrat
apolipoprotein
b
clearli
retrotransloc
channel
cotransl
target
erad
cholera
toxin
also
appear
util
leav
mammalian
er
journey
plasma
membran
back
secretori
pathway
ultim
cytoplasm
also
see
sect
iid
howev
anoth
yeast
erad
substrat
depend
function
yeast
derlin
homolog
contribut
derlin
consist
find
antibodi
protein
thwart
retrotransloc
model
substrat
mammalian
er
vesicl
domin
neg
form
derlin
disrupt
viralinduc
retrotransloc
degrad
mhc
class
molecul
see
sect
iif
moreov
derlin
recruit
provid
energi
requir
drive
erad
substrat
er
see
add
alreadi
complex
situat
yeast
derlin
interact
ligas
implic
retrotransloc
er
lumin
protein
degrad
hmgcoa
reductas
yeast
homolog
may
act
similarli
togeth
studi
highlight
enigmat
natur
retrotransloc
process
suggest
one
mani
proteinscomplex
may
provid
channel
requir
erad
channel
may
compos
sever
differ
protein
erad
substrat
mechan
forc
necessari
remov
protein
er
lumen
membran
provid
cytoplasm
aaa
atpas
also
known
valosincontain
protein
vcp
yeast
function
sever
cellular
process
includ
cell
divis
membran
fusion
process
membraneassoci
transcript
factor
fact
mutat
protein
give
rise
complex
syndrom
inclus
bodi
myopathi
associ
paget
diseas
bone
frontotempor
dementia
role
proteasomedepend
degrad
first
emerg
yeast
genet
screen
given
divers
activ
make
sens
interact
wide
rang
partner
provid
specif
atpas
energycoupl
function
thu
erad
complex
contain
requir
extract
solubl
integr
membran
polyubiquitin
substrat
er
degrad
also
interact
ligas
place
ideal
posit
aid
retrotransloc
polyubiquitin
protein
follow
extract
protein
must
usher
proteasom
except
two
cytosol
protein
yeast
ident
factor
particip
step
clear
membran
protein
pose
formid
challeng
substrat
retrotransloc
intact
therefor
hydrophob
membranespan
domain
expos
aqueou
environ
cytoplasm
must
protect
recent
studi
suggest
protein
complex
particip
recognit
tailanchor
protein
ribosom
may
help
maintain
membran
protein
solubl
form
en
rout
proteasom
howev
complex
seem
recogn
membranespan
region
associ
substrat
probabl
region
prone
aggreg
erad
substrat
proteolysi
occur
cytoplasm
via
action
proteasom
proteasom
larg
mda
protein
complex
subdivid
two
main
assembl
core
particl
regulatori
particl
also
known
cap
polyubiquitin
tag
substrat
recogn
either
subunit
proteasom
cap
andor
proteasomeassoci
protein
recognit
substrat
must
deubiquitin
deubiquitin
enzym
dub
exampl
subunit
cap
deubiquitin
proteasom
substrat
prerequisit
degrad
import
maintain
high
level
free
ubiquitin
dub
also
propos
remov
ubiquitin
linkag
substrat
thread
largescal
proteom
analysi
identifi
dub
associ
two
partner
knockdown
stabil
erad
cytosol
ubiquitin
substrat
suggest
dub
regul
function
contrast
dub
interact
substrat
prior
proteasom
associ
trim
ubiquitin
chain
delay
substrat
degrad
proteasom
core
contain
three
distinct
proteolyt
activ
trypsinlik
chymotrypsinlik
caspaselik
net
result
proteasomemedi
degrad
gener
small
amino
acid
peptid
process
cellular
proteas
sever
proteasom
inhibitor
discov
target
differ
activ
proteasom
proven
use
determin
contribut
ubiquitinproteasom
system
up
regul
cellular
pathway
includ
erad
exampl
acetylleuleunorleucin
alln
cbzleuleuleucin
revers
inhibitor
chymotrypsinlik
activ
laid
foundat
discoveri
proteasom
inhibitor
use
clinic
ie
bortezomib
see
sect
iiia
section
focu
six
exampl
erad
directli
link
human
health
diseas
also
provid
tabl
tabl
includ
diseas
connect
erad
pathway
pace
research
newli
discov
rare
diseas
rapid
mani
diseaserelev
protein
insuffici
data
classifi
eradlink
tabl
exhaust
goal
instead
illustr
divers
natur
diseas
link
pathway
includ
tabl
demonstr
protein
er
retentionimpair
traffick
togeth
either
proteasomedepend
degrad
andor
polyubiquitin
first
diseas
unambigu
link
erad
pathway
cystic
fibrosi
cf
cf
caus
defect
chlorid
transport
cftr
mutat
cftr
alter
salt
water
balanc
across
varieti
epithelia
result
main
clinic
featur
cf
delay
growth
due
digest
nutrientrel
disord
sever
constip
mucu
buildup
lung
result
recur
prolong
infect
diseasecaus
allel
report
cftr
estim
caucasian
american
carri
mutant
cf
allel
current
approv
treatment
support
focu
reduc
number
durat
lung
infect
provid
diet
supplement
meet
patient
nutrit
need
unfortun
averag
life
expect
cf
patient
year
valu
increas
significantli
past
three
decad
due
devast
natur
diseas
preval
larg
research
effort
devot
uncov
molecular
mechan
underli
cf
effort
includ
studi
cftr
channel
activ
regul
cftr
fold
earli
secretori
pathway
cftr
traffick
secretori
pathway
studi
identifi
modifi
diseas
phenotyp
also
undertaken
see
exampl
ref
cftr
member
atpbind
cassett
abc
famili
transport
name
impli
coupl
atp
hydrolysi
solut
transport
cftr
perhap
wide
recogn
member
abc
famili
diseas
also
attribut
mutat
abc
famili
member
see
tabl
gener
abc
transport
multipass
integr
membran
protein
contain
two
membranespan
domain
msd
follow
nucleotidebind
domain
nbd
howev
cftr
uniqu
among
abc
transport
function
ion
channel
possess
regulatori
r
domain
lie
second
msd
cftr
channel
open
regul
part
protein
kinas
amedi
phosphoryl
r
domain
tightli
coupl
nucleotid
bind
nbd
base
size
amino
acid
complex
domain
organ
even
wildtyp
form
cftr
encount
signific
number
hurdl
synthesi
fact
cftr
begin
fold
cotransl
even
though
posttransl
fold
event
must
also
take
place
protein
achiev
nativ
conform
aid
fold
select
misfold
speci
erad
nascent
cftr
engag
cytoplasm
er
lumin
chaperon
addit
portion
protein
enter
er
nascent
cftr
nglycosyl
produc
immatur
erloc
form
term
band
b
speci
interact
lectinlik
chaperon
resid
er
ie
calnexin
calreticulin
fold
upon
er
exit
core
glycan
structur
elabor
golgi
apparatu
decreas
cftr
electrophoret
mobil
polyacrylamid
gel
lead
presenc
band
c
speci
commonli
design
matur
form
found
plasma
membran
consist
mani
fold
hurdl
much
wildtyp
cftr
degrad
soon
synthesi
although
condit
epitheli
cell
wildtyp
protein
may
matur
quit
well
common
diseasecaus
mutant
allel
cftr
delet
phenylalanin
posit
mutat
caus
virtual
protein
misfold
prevent
fold
either
case
lead
degrad
howev
mutat
partial
reduc
channel
function
comput
structur
evid
suggest
mutat
disrupt
interact
cytoplasm
loop
within
consist
data
earlier
crosslink
experi
suggest
mutat
alter
msd
pack
interestingli
rescu
form
reach
plasma
membran
also
subject
protein
qualiti
control
target
lysosom
degrad
chaperon
ubiquitin
ligas
act
erad
see
ref
although
cf
patient
possess
least
one
allel
anoth
diseasecaus
mutat
cftr
result
channel
gate
defect
rather
traffick
defect
earli
studi
reveal
present
band
b
result
suggest
protein
process
golgiresid
enzym
diseas
link
er
qualiti
control
phenomenon
consist
hypothesi
ward
kopito
show
immatur
wildtyp
form
cftr
mutant
form
cftr
degrad
soon
translat
thu
lysosom
deliveri
inde
level
unaffect
inhibitor
lysosom
proteas
degrad
insensit
treatment
fungal
toxin
brefeldin
bfa
prevent
er
golgi
traffick
even
though
role
up
destroy
secretori
pathway
protein
yet
observ
parallel
studi
kopito
riordan
lab
next
demonstr
proteolysi
er
resid
form
cftr
requir
activ
cytoplasm
proteasom
togeth
data
establish
first
direct
link
diseas
caus
mutat
protein
erad
proteasometarget
protein
cftr
polyubiquitin
select
degrad
use
cellfre
assay
found
polyubiquitin
occur
cotransl
nascent
chain
associ
ribosom
moreov
polyubiquitin
accumul
insolubl
form
activ
proteasom
compromis
data
suggest
amelior
cflink
maladi
would
requir
elabor
treatment
simpli
inhibit
degrad
see
sect
iiia
fact
nonspecif
chemic
chaperon
osmolyt
improv
protein
fold
environ
cell
partial
repair
fold
defect
band
c
channel
activ
becam
evid
also
see
sect
iiia
tabl
incub
cell
low
temperatur
similarli
repair
fold
defect
consist
exhibit
featur
classic
temperaturesensit
foldingcompromis
mutant
sinc
much
work
devot
character
ubiquitin
machineri
mediat
qualiti
control
establish
specif
ubiquitin
ligas
trivial
mammal
encod
enzym
see
often
overlap
specif
partial
redund
function
date
three
ligas
best
candid
implic
directli
erad
cftr
includ
cytoplasm
protein
chip
integr
er
membran
protein
sinc
fold
defect
may
occur
one
sever
point
cftr
synthesi
surpris
one
facilit
ubiquitin
cftr
howev
unclear
coordin
target
cftr
degrad
one
possibl
differ
work
sequenti
manner
ubiquitin
cftr
eg
coand
posttransl
evid
scenario
come
studi
overexpress
either
chip
decreas
level
wildtyp
cftr
howev
chip
show
differ
prefer
mutant
form
cftr
name
cftr
contain
mutat
within
sensit
wherea
cftr
truncat
sensit
chip
express
data
suggest
act
cftr
cotransl
recogn
earli
fold
defect
assist
select
chaperon
see
wherea
chip
recogn
fold
defect
cftr
translat
complet
protein
qualiti
control
chaperon
function
tightli
intertwin
see
therefor
target
chaperon
associ
ligas
may
either
facilit
degrad
misfold
protein
suggest
prevent
prematur
degrad
cftr
thu
chaperon
modul
may
provid
mean
fold
escap
erad
ultim
function
albeit
less
effici
plasma
membran
fact
effect
scheme
rescu
recent
achiev
alter
activ
cochaperon
function
step
chaperon
erassoci
decreas
level
sirna
increas
cftr
fold
effici
silenc
combin
small
molecul
corrector
corrector
partial
rescu
matur
also
see
sect
iiia
strong
synergist
effect
cftr
matur
evid
data
emphas
import
target
degrad
fold
machineri
achiev
maxim
therapeut
effect
molecular
chaperon
act
erad
gatekeep
close
monitor
protein
fold
regul
decis
fold
degrad
remain
mysteri
chaperon
engag
protein
fold
degrad
process
one
possibl
amount
time
client
protein
interact
chaperon
critic
decis
model
protein
fold
expos
chaperonebind
site
go
sever
cycl
bind
releas
protein
attain
final
conform
site
obscur
protein
releas
er
traffic
golgi
howev
bind
site
remain
access
chaperon
extend
period
time
bound
chaperon
may
recruit
degrad
machineri
notabl
chaperon
suggest
act
bridg
factor
misfold
protein
ligas
support
model
regul
degrad
togeth
ligas
chip
also
see
ref
support
model
cytosol
interact
longer
wildtyp
cftr
enhanc
interact
chaperon
pair
observ
also
mysteri
distinct
chaperon
may
exhibit
profold
versu
prodegrad
effect
differ
substrat
studi
yeast
show
act
prodegrad
manner
cftr
qualiti
control
cytoplasm
play
import
role
maintain
solubl
facilit
cftr
fold
specif
perturb
function
either
genet
ablat
yeast
chemic
inhibit
mammalian
cell
acceler
degrad
cftr
cftr
respect
substrat
promot
erad
mammal
atpas
activ
intrins
low
cochaperon
bind
stimul
atpas
activ
sinc
promot
cftr
fold
one
might
predict
increas
level
might
promot
cftr
matur
unexpectedli
increas
acceler
cftr
degrad
decreas
level
rescu
foldingmatur
one
explan
result
slow
rate
cycl
benefit
cftr
matur
acceler
cycl
cftr
matur
compromis
protein
deliv
soon
degrad
machineri
ultim
like
addit
chaperon
cochaperon
might
becom
therapeut
target
treat
cf
discov
augment
matur
addit
cftr
abc
transport
identifi
substrat
erad
includ
multidrug
resist
protein
pglycoprotein
breast
cancer
resist
protein
bcrp
see
tabl
pglycoprotein
bcrp
member
mdrtap
white
subfamili
abc
transport
respect
key
function
multidrug
resist
protein
atpdepend
export
xenobiot
administ
chemotherapeut
drug
resist
major
clinic
problem
impact
effect
treatment
mani
diseas
especi
cancer
fact
sequenc
studi
found
bcrp
variant
dramat
effect
protein
level
methotrex
transport
measur
bcrp
activ
find
suggest
variant
affect
either
protein
biosynthesi
traffick
particular
cell
contain
one
two
allel
produc
compar
amount
mrna
compar
express
wildtyp
bcrp
reduc
protein
level
also
shown
mutant
protein
produc
variant
remain
sensit
endoglycosidas
h
endo
h
higher
eukaryot
cell
nglycosyl
protein
transit
golgi
glycan
process
golgi
ii
render
glycoprotein
insensit
endo
h
therefor
prolong
sensit
endo
h
indic
er
retent
furthermor
mutant
ubiquitin
protein
level
increas
cell
incub
proteasom
inhibitor
note
data
strongli
suggest
bcrp
variant
retain
er
target
erad
diseas
directli
caus
mutant
form
transport
correl
polymorph
patient
respons
chemotherapeut
document
therefor
import
understand
mechan
regul
express
multidrug
transport
underestim
knowledg
may
help
predict
patient
respond
chemotherapeut
addit
new
strategi
combat
drugresist
tumor
may
develop
sever
disord
result
accumul
erad
substrat
neuron
cell
neuron
cell
rel
low
regen
capac
agedepend
decreas
abil
withstand
cellular
stress
render
particularli
sensit
toxic
aggreg
result
apoptosi
gener
neurodegen
diseas
caus
mental
impair
movement
disord
seen
alzheim
diseas
ad
ad
accumul
incorrectli
process
form
amyloid
precursor
protein
term
amyloid
beta
thought
link
neurodegen
phenotyp
ad
accumul
propos
result
neurodegener
due
mitochondri
dysfunct
oxid
stress
disrupt
synapt
transmiss
disrupt
axon
traffick
andor
gener
membran
disrupt
specif
molecular
defect
due
accumul
remain
determin
patholog
diseas
highlight
sensit
neuron
cell
aggreg
aggregationpron
protein
although
sever
exampl
neurodegen
diseas
follow
typic
erad
paradigm
protein
misfold
follow
proteasomedepend
degrad
tabl
focu
discuss
two
neurodegen
diseas
link
erad
machineri
somewhat
atyp
fashion
huntington
diseas
hd
result
abnorm
high
number
polyglutamin
polyq
repeat
huntingtin
htt
protein
hd
length
cag
codon
repeat
htt
posit
correl
increas
propens
htt
aggreg
format
line
observ
length
cag
repeat
htt
also
directli
correl
age
onset
diseas
sever
hd
patient
diseas
inherit
autosom
domin
pattern
afflict
nearli
american
adultonset
hd
patient
present
combin
behavior
chang
movement
disord
progress
dementia
nativ
function
htt
poorli
understood
unusu
natur
link
hd
erad
stem
fact
htt
cytoplasm
protein
instead
secretori
protein
earli
hint
up
might
connect
pathogenesi
hd
came
studi
demonstr
hd
inclus
brain
section
affect
individu
immunoreact
ubiquitin
possibl
function
link
hd
up
provid
kopito
lab
show
up
less
activ
cell
express
polyq
htt
specif
length
polyq
repeat
increas
beyond
threshold
correl
diseas
present
abil
proteasom
degrad
fluoresc
report
cell
inhibit
data
provid
one
mechanist
explan
hd
develop
gener
htt
polyq
aggreg
decreas
up
activ
lead
accumul
unprocess
up
substrat
escal
aggreg
toxic
howev
still
debat
whether
hd
aggreg
secondari
effect
diseas
caus
neurodegener
thu
misfold
htt
preaggreg
might
also
accumul
may
initi
diseas
onset
nevertheless
support
up
inhibit
model
come
studi
examin
level
ubiquitinlink
proteasomedirect
peptid
present
htt
polyqexpress
cell
line
tissu
taken
mous
model
hd
experiment
system
signific
increas
amount
ubiquitin
peptid
present
sampl
contain
htt
report
polyq
repeat
furthermor
chain
accumul
correl
strongli
proteasom
inhibit
howev
possibl
increas
link
chain
result
accumul
polyubiquitin
htt
aggreg
rather
global
impair
proteasom
test
global
impair
level
ubiquitin
chain
linkag
ie
examin
level
ubiquitin
chain
increas
presenc
either
polyq
repeat
form
htt
point
toward
wholesal
dysregul
up
erad
substrat
also
accumul
condit
answer
appear
ye
duennwald
lindquist
found
concentr
sever
wellcharacter
erad
substrat
increas
presenc
aggregationpron
htt
accumul
erad
substrat
may
aris
direct
proteasom
inhibit
suggest
andor
observ
coloc
htt
inclus
also
recent
studi
report
vitro
interact
htt
polyq
aggreg
erresid
ubiquitin
ligas
requir
erad
sever
substrat
htt
aggreg
block
associ
polyubiquitin
protein
erad
substrat
accumul
one
might
predict
upr
induc
presenc
polyq
htt
fact
connect
longterm
upr
induct
apoptosi
see
sect
id
might
explain
least
part
neurodegen
phenotyp
hd
inde
express
polyq
htt
yeast
activ
upr
synthet
lethal
combin
induc
er
stress
tunicamycin
inhibitor
nlink
glycosyl
studi
mammalian
cell
show
polyq
htt
induc
cell
stress
increas
chaperon
level
result
convers
perk
activ
phosphoryl
form
togeth
data
strongli
suggest
polyq
htt
aggreg
alter
activ
erad
machineri
induc
upr
contribut
cytotox
say
htt
polyq
preaggreg
nt
also
contribut
diseas
fact
propos
mechan
pathogenesi
hd
stem
disrupt
pathway
either
aberr
interact
loss
htt
function
exampl
htt
local
golgi
endosom
vesicular
carrier
among
locat
cell
htt
function
axon
traffick
block
due
polyq
htt
could
lead
decreas
synapt
transmiss
cell
death
togeth
futur
therapi
hd
may
need
focu
address
cytotox
associ
er
stress
anoth
exampl
neurolog
diseas
link
erad
pathway
parkinson
diseas
pd
pd
member
famili
movement
disord
result
loss
dopaminerg
neuron
pd
occur
popul
usual
develop
year
age
patient
pd
present
four
main
categori
symptom
tremor
bradykinesia
rigid
postur
instabl
probabl
develop
pd
increas
age
either
sporad
aris
specif
genet
mutat
instanc
mutat
encod
ubiquitin
ligas
parkin
lead
autosomalrecess
form
earlyonset
pd
parkin
normal
local
cytoplasm
except
chip
see
gener
atyp
ligas
particip
erad
howev
demonstr
parkin
induc
upr
addit
candid
parkin
substrat
parkinassoci
endothelin
receptorlik
receptor
paelr
paelr
also
known
put
g
proteincoupl
receptor
highli
express
central
nervou
system
endogen
ligand
found
connect
paelr
pd
support
observ
paelr
accumul
lewi
bodi
electrondens
inclus
serv
histolog
indic
pd
furthermor
paelr
polyubiquitin
cell
ubiquitin
parkin
vitro
addit
proteasomedepend
degrad
paelr
stimul
parkin
overexpress
final
paelr
accumul
detergentinsolubl
fraction
cell
treat
proteasom
inhibitor
er
stressor
indic
paelr
natur
propens
misfold
stress
condit
data
indic
parkin
mediat
qualiti
control
paelr
anoth
connect
parkin
erad
provid
observ
parkin
function
may
supplant
anoth
requir
erad
select
substrat
mammal
modul
level
chang
paelr
level
express
protect
paelrinduc
cell
death
furthermor
express
dopaminerg
neuron
throughout
mous
brain
provid
addit
evid
parkin
function
might
coordin
howev
parkin
also
implic
mitophagi
process
mitochondria
engulf
destroy
via
autophagyrel
pathway
found
mitochondri
serinethreonin
kinas
accumul
damag
mitochondria
turn
recruit
parkin
parkin
ubiquitin
mitochondria
fusionpromot
factor
mitofusin
result
degrad
mitofusin
via
eradlik
process
mitofusin
degrad
trigger
mitophagi
pathway
appear
import
pathogenesi
pd
mutat
also
caus
inherit
pd
howev
relationship
rel
import
mitochondri
er
function
parkin
remain
determin
past
year
commun
mitochondria
er
establish
mitochondria
directli
interact
er
interact
import
mani
process
includ
lipid
transfer
calcium
signal
cell
death
also
factor
compris
erad
machineri
also
function
recogn
extract
destroy
compon
resid
mitochondri
membran
recent
studi
reveal
parkin
upregul
er
stress
also
mitochondri
stress
surprisingli
howev
cytoprotect
effect
associ
parkin
express
may
occur
independ
proteasom
collect
data
highlight
enigmat
natur
parkin
true
function
need
examin
parkin
role
interfac
erad
diseas
diabet
mellitu
metabol
diseas
individu
either
produc
littl
insulin
unabl
respond
properli
insulin
result
hyperglycemia
gener
diabet
broken
two
main
class
base
underli
caus
diseas
andor
condit
surround
onset
symptom
type
diabet
account
case
usual
diagnos
young
age
type
diabet
result
immun
systemmedi
destruct
pancreat
therebi
decreas
level
insulin
contrast
type
diabet
account
major
case
result
primarili
insulin
resist
due
decreas
abil
target
cell
respond
insulin
diabet
individu
present
rang
shortterm
longterm
symptom
includ
blind
heart
diseas
kidney
failur
need
limb
amput
due
poor
circul
classif
patient
type
type
sometim
difficult
due
larg
number
diseas
modifi
purpos
review
focu
genet
factor
caus
diabet
directli
link
erad
normal
peptid
hormon
insulin
produc
pancreat
stimul
clearanc
blood
glucos
muscl
fat
liver
cell
clearanc
achiev
via
interact
insulin
receptor
cell
therebi
initi
signal
cascad
pancreat
special
highli
elabor
secretori
system
design
synthes
export
larg
amount
insulin
hyperglycem
condit
fact
insulin
product
cell
account
total
protein
synthesi
stimul
condit
insulin
biosynthesi
begin
cotransl
insert
amino
acid
preproinsulin
er
subsequ
remov
signal
sequenc
precursor
gener
amino
acid
peptid
proinsulin
oxid
environ
er
proinsulin
acquir
three
disulfid
bond
follow
export
golgi
complex
proteolyt
process
proinsulin
result
product
matur
insulin
packag
secretori
granul
demand
place
biosynthet
fold
machineri
insulin
product
suggest
result
increas
amount
er
stress
discuss
earlier
unresolv
activ
upr
lead
apoptosi
heterozyg
mice
unabl
activ
one
leg
upr
mediat
perk
becom
diabet
glucos
intoler
mice
upr
signal
partial
inhibit
develop
insulin
resist
thu
anticip
apoptosi
relev
type
type
diabet
er
stress
may
play
signific
role
cell
death
insulin
defici
event
suggest
presenc
positivefeedback
loop
stress
destroy
turn
potenti
diseas
due
decreas
abil
produc
insulin
consist
link
insulin
product
upr
diabet
er
stress
increas
diabet
akita
mous
model
case
diseas
aris
express
singl
copi
insulin
mutant
unabl
form
intrachain
disulfid
bond
interestingli
level
wildtyp
insulin
increas
presenc
impli
even
nativ
insulin
subject
misfold
proteasomedepend
degrad
support
role
er
stress
pathogenesi
diabet
come
find
guanabenz
small
molecul
rescu
cell
death
result
exposur
er
stressor
includ
tunicamycin
express
investig
mechan
action
guanabenz
reveal
rescu
due
enhanc
uprmedi
translat
attenu
find
repres
novel
approach
mitig
er
stress
may
use
treat
metabol
syndrom
associ
misfold
insulin
variant
peptid
hormon
data
describ
suggest
allel
variant
insulin
human
may
contribut
normal
level
er
stress
phenomenon
may
push
cell
edg
lead
apoptosi
diabet
support
model
sever
point
mutat
insulin
gene
identifi
patient
neonat
diabet
identifi
mutat
result
er
accumul
proinsulin
accompani
secret
defect
interestingli
one
natur
occur
mutat
one
found
akita
mous
studi
akita
model
demonstr
robust
ubiquitin
directli
implic
erad
pathway
pathogenesi
genet
link
diabet
mous
model
induc
express
confirm
relationship
er
stress
increas
apoptosi
diabet
note
apoptot
respons
increas
either
proteasom
inhibit
downregul
member
complex
therefor
erad
play
import
role
mitig
stress
incur
upon
express
misfold
insulin
diabetescaus
mutat
also
identifi
insulin
receptor
ir
target
mutant
receptor
erad
ir
synthes
immatur
form
must
undergo
posttransl
modif
includ
nglycosyl
dimer
proteolyt
cleavag
substitut
highli
conserv
posit
arg
prevent
receptor
dimer
reduc
transport
cell
surfac
decreas
level
mutant
ir
precursor
time
suggest
protein
degrad
analysi
anoth
ir
variant
reveal
mutant
exhibit
enhanc
interact
bip
indic
increas
er
retent
perhap
recognit
degrad
two
addit
ir
variant
identifi
patient
insulin
resist
result
decreas
surfac
express
coupl
increas
degrad
proreceptor
form
studi
reveal
proreceptor
level
increas
upon
addit
proteasom
inhibitor
addit
mutant
form
ir
associ
cytosol
greater
extent
wildtyp
ir
defin
role
ir
degrad
antibodi
microinject
cell
transfect
mutant
ir
treatment
increas
amount
mutant
ir
suggest
cytosol
enhanc
degrad
mutant
ir
contrast
chemic
inhibit
increas
proteasomedepend
degrad
wildtyp
immatur
form
ir
suggest
chaperon
also
facilit
format
earli
biogen
intermedi
receptor
pathogen
bacteria
includ
vibrio
cholera
bordetella
pertussi
shigella
dysenteria
shiga
toxigen
escherichia
coli
infect
hundr
million
peopl
year
combin
infect
result
million
death
annual
exampl
vibrio
cholera
seriou
threat
develop
nation
estim
infect
million
person
year
result
death
infecti
outbreak
occur
primarili
nation
due
poor
sanit
inadequ
medic
care
patient
infect
pathogen
variant
vibrio
cholera
present
abruptonset
wateri
diarrhea
danger
level
fluid
loss
properli
treat
death
result
within
hour
key
vibrio
cholera
virul
begin
secret
protein
complex
alter
host
cellular
homeostasi
toxin
famili
consist
four
subfamili
base
method
toxin
entri
host
cell
via
b
subunit
upon
enzymat
activ
subunit
cholera
toxin
ctx
compos
bhomopentam
disulfidelink
catalyt
link
domain
holotoxin
intern
apic
plasma
membran
enterocyt
follow
cell
surfac
interact
gangliosid
entri
endosom
ctx
traffick
retrograd
manner
golgi
possibl
due
associ
gangliosid
retrograd
traffick
ctx
er
occur
via
kdel
receptor
recogn
kdel
er
retriev
signal
subunit
er
catalyt
subunit
disassoci
subunit
due
action
er
oxidoreductas
retrotransloc
er
cytoplasm
fold
catalyz
addit
adpribosyl
group
onto
g
subunit
adenyl
cyclas
result
constitut
activ
adenyl
cyclas
increas
camp
product
continu
activ
cftr
overact
cftr
caus
diarrhea
result
water
electrolyt
loss
retrotransloc
er
cytoplasm
appear
follow
eradlik
pathway
observ
erad
toxin
must
first
recogn
prior
retrotransloc
interestingli
recognit
involv
erresid
pdi
pdi
function
oxidoreductas
unfold
reaction
rather
redoxdepend
chaperon
one
model
pdi
direct
unfold
found
depend
anoth
er
oxidoreductas
help
pdi
cycl
reduc
toxin
bind
oxid
toxin
releas
state
anoth
model
spontan
unfold
dissoci
pdi
unlik
erad
substrat
retrotransloc
drive
forc
retrotransloc
er
cytosol
one
possibl
extract
cap
proteasom
suffici
remov
pro
yeast
mammalian
vesicl
howev
data
directli
support
role
cap
disloc
current
lack
yet
anoth
hypothesi
spontan
refold
cytosol
ratchet
retrotranslocon
simultan
help
avoid
recognit
cytosol
qualiti
control
machineri
evid
support
yet
anoth
model
deriv
fact
cytosol
chaperon
interact
atpdepend
manner
requir
er
disloc
final
treatment
cell
multifunct
drug
acid
pba
inhibit
cholera
intox
contrast
mode
action
see
sect
iiia
pba
may
stabil
tertiari
structur
sinc
compound
increas
thermal
stabil
assess
circular
dichroism
fluoresc
spectroscopi
cell
line
treat
pba
also
exhibit
reduc
transloc
er
cytoplasm
spare
intox
three
protein
implic
retrotranslocon
schmitz
et
al
use
cellfre
system
examin
role
retrotransloc
show
retrotransloc
microsom
process
inhibit
addit
ribosom
nascent
chain
complex
block
contrast
retrotransloc
subunit
facilit
human
embryon
kidney
cell
interact
reduc
retrotransloc
evid
cell
express
dominantneg
version
also
interact
pdi
could
provid
conveni
mechan
hand
holotoxin
retrotranslocon
recent
interact
ligas
note
besid
function
implic
retrotransloc
hmgcoa
reductas
cpi
yeast
see
sect
ie
consist
data
downregul
use
dominantneg
mutant
attenu
retrotransloc
interestingli
dominantneg
form
also
block
interact
suggest
interact
prior
ligas
collect
data
support
role
multipl
put
channel
retrotransloc
although
unclear
act
togeth
sequenti
redundantli
retrotransloc
unknown
escap
polyubiquitin
proteasomedepend
degrad
typic
fate
erad
substrat
hypothes
avoid
polyubiquitin
two
lysin
may
inaccess
modif
direct
ubiquitin
observ
one
studi
demonstr
retrotransloc
continu
lysineless
version
howev
note
section
ie
ubiquitin
note
noncanon
site
ser
thr
therefor
role
ligas
ubiquitin
retrotransloc
remain
uncertain
altern
possibl
polyubiquitin
may
act
upon
deubiquitin
enzym
rescu
protein
degrad
rapid
refold
cytoplasm
see
may
obscur
residu
might
otherwis
ubiquitin
model
support
data
show
rapid
acquisit
trypsin
resist
upon
releas
pdi
overal
studi
reveal
intox
requir
function
erad
machineri
masquerad
erad
substrat
albeit
one
uniqu
featur
toxin
structur
similar
seem
evolv
similar
mechan
coopt
erad
machineri
understand
factor
process
requir
ctx
toxic
might
provid
use
target
treatment
symptom
result
pathogen
bacteria
harbor
toxin
fact
ricin
plant
toxin
produc
ricinu
comminu
may
spontan
unfold
dissoci
pdi
er
also
appear
forego
ubiquitin
retrotransloc
either
retrotranslocon
sinc
ricin
synthes
within
eukaryot
cell
rather
bacteria
like
ctx
glycosyl
er
may
explain
observ
differ
fate
ricin
interact
ricin
measur
amount
degrad
ricin
toxin
cytoplasm
presum
due
failur
effici
transloc
er
complet
refold
retrotransloc
famili
serin
proteas
inhibitor
serpin
respons
class
diseas
known
serpinopathi
diseas
result
mutat
serpin
famili
member
includ
neuroserpin
antithrombin
mutant
serpin
adopt
alter
unstabl
conform
lead
loss
nativ
protein
function
case
acquisit
toxic
gainoffunct
aggreg
polym
net
outcom
group
patholog
result
lung
liver
diseas
dementia
blood
clot
defici
member
serpin
famili
share
sequenc
homolog
well
conserv
tertiari
structur
mutat
encod
prototyp
serpin
result
defici
approxim
peopl
northern
european
descent
homozyg
diseasecaus
allel
atdefici
patient
may
present
chronic
obstruct
pulmonari
diseas
copd
develop
cirrhosi
among
individu
affect
defici
nearli
develop
copd
symptom
exacerb
smoke
liver
diseas
common
infant
born
jaundic
homozyg
adult
age
evid
cirrhosi
death
observ
highlight
progress
natur
defici
need
earli
diagnosi
current
treatment
atassoci
copd
reli
intraven
enzym
replac
therapi
much
difficult
treat
cirrhosi
result
polym
accumul
viabl
option
liver
transplant
therefor
signific
bodi
research
devot
uncov
pathway
degrad
misfold
hope
develop
therapi
reduc
polym
format
andor
increas
protein
clearanc
liver
acid
protein
synthes
primarili
hepatocyt
er
becom
nglycosyl
function
bloodstream
inhibit
neutrophilderiv
proteas
lung
tissu
regul
elastas
wildtyp
protein
known
allel
bind
cleav
proteas
therebi
induc
conform
chang
inactiv
common
diseasecaus
variant
term
z
variant
atz
base
slower
migrat
isoelectr
focus
gel
rel
atm
due
inher
instabl
loss
intramolecular
salt
bridg
atz
selfassoci
form
dimer
higher
order
polym
within
er
hepatocyt
result
serum
level
wildtyp
level
essenc
atz
selfassembl
underli
two
main
patholog
associ
defici
defici
lossoffunct
diseas
consequ
increas
elastas
activ
result
destruct
connect
tissu
lung
defici
gainoffunct
diseas
accumul
toxic
aggreg
liver
lead
hepat
cirrhosi
increas
risk
hepatocellular
carcinoma
earli
work
mammalian
cell
yeast
model
demonstr
atz
degrad
requir
activ
proteasom
point
toward
role
erad
clear
solubl
form
atz
secretori
pathway
first
atz
degrad
significantli
delay
yeast
strain
lack
chymotrypsinlik
activ
proteasom
strain
proteasom
assembl
defect
second
halflif
atz
express
human
skin
fibroblast
increas
threefold
presenc
proteasom
inhibitor
proteasom
also
requir
degrad
natur
occur
truncat
version
null
hong
kong
nhk
surprisingli
remain
unclear
whether
mutant
ubiquitin
prior
degrad
although
may
involv
atz
turnov
nhk
resid
complex
moreov
dominantneg
construct
decreas
ubiquitin
nhk
hela
cell
atz
solubl
degrad
enhanc
overexpress
work
demonstr
atm
interact
calnexin
matur
therefor
surpris
lectin
play
import
role
erad
misfold
form
atz
shown
interact
calnexin
patient
fibroblast
transfect
atz
gene
similar
interact
demonstr
nhk
ongo
studi
use
nhk
yield
addit
insight
machineri
requir
degrad
misfold
form
exampl
calnexinbound
nhk
appear
transfer
sequenti
manner
see
sect
ie
perhap
retrotranslocon
anoth
studi
suggest
role
nhk
degrad
celltyp
specif
ermani
may
instead
critic
timer
chose
nhk
degrad
nevertheless
ermani
act
synergist
trigger
degrad
nhk
nhk
also
bind
two
lectin
bip
act
earli
pathway
erad
substrat
select
increas
evid
indic
autophagi
may
play
complementari
role
erad
destroy
difficulttomanag
protein
autophag
pathway
remov
larg
aggreg
even
signific
portion
damag
er
one
might
imagin
autophagi
could
clear
higher
order
atz
polym
earli
evid
hypothesi
came
studi
examin
atz
polym
resid
immunoelectron
microscopi
predict
atz
found
er
also
autophagosom
notabl
chemic
disruptor
autophagi
stabil
atz
albeit
rather
modestli
compar
proteasom
inhibit
evid
corrobor
use
yeast
model
shown
autophagi
becam
necessari
degrad
atz
protein
overexpress
aggreg
ultim
import
autophag
pathway
fate
atz
demonstr
mous
model
model
prove
essenti
test
small
molecul
might
one
day
improv
patholog
associ
defici
see
sect
iiia
overal
level
atz
express
compon
regul
autophagi
may
repres
genet
modifi
defici
identif
genet
modifi
vital
given
atz
homozygot
develop
clinic
relev
liver
diseas
childhood
surprisingli
serpin
famili
member
exhibit
serin
proteas
inhibitor
activ
instead
function
chaperon
resid
er
aid
assembl
procollagen
triplehel
form
procollagen
mutat
compromis
chaperon
function
point
mutat
appear
result
toxic
polymer
instead
loss
function
manifest
osteogenesi
imperfecta
due
delay
secret
procollagen
trimer
patient
fibroblast
virtual
detect
level
protein
howev
treatment
increas
level
suggest
erad
pathway
play
role
form
diseas
contrast
aggreg
aris
er
directli
mutant
form
procollagen
also
caus
osteogenesi
imperfecta
destroy
autophagi
mention
addit
serpinopathi
describ
three
mutant
form
serpin
exist
er
retain
defect
protein
lead
thyroxin
bind
globulin
defici
defici
type
hereditari
angioedema
remain
unknown
whether
mutant
protein
target
erad
andor
autophagi
base
fate
mutant
serpin
like
pathway
contribut
turnov
addit
bacteria
select
virus
also
evolv
way
subvert
host
cell
capit
eradassoci
activ
immun
surveil
viral
infect
cell
requir
present
viral
peptid
mhci
molecul
cytotox
cell
gener
viral
peptid
accomplish
proteasom
process
cleavag
proteas
follow
load
onto
mhci
er
traffick
cell
surfac
mhci
biosynthesi
complex
requir
disulfid
bond
format
nlink
glycosyl
heterodimer
peptid
load
failur
properli
assembl
complex
result
erad
one
exampl
turnov
mhci
molecul
acceler
infect
human
cytomegaloviru
hcmv
hcmv
herpestyp
viru
caus
persist
latent
infect
usual
lifethreaten
immunocompromis
individu
individu
hcmv
lead
mononucleosislik
symptom
includ
fatigu
joint
stiff
muscl
pain
viru
also
target
specif
organ
eye
lung
gastrointestin
tract
brain
studi
mhci
downregul
contribut
significantli
earli
investig
erad
two
viral
gene
identifi
direct
newli
synthes
mhci
molecul
erad
pathway
earli
studi
also
demonstr
retrotransloc
fulllength
mhci
cytoplasm
pool
presenc
retrotransloc
disloc
materi
deglycosyl
may
import
feed
protein
proteasom
hcmvinduc
degrad
mhci
also
requir
polyubiquitin
interestingli
ubiquitin
occur
cytoplasm
tail
mhci
suggest
ubiquitin
occur
lumin
domain
mhci
thu
protein
must
form
hairpin
across
er
membran
least
partial
retrotransloc
requir
mhci
ubiquitin
surpris
bip
play
role
degrad
mhci
interestingli
differ
machineri
use
involv
derlin
retrotransloc
contrast
requir
signal
peptid
peptidas
spp
retrotransloc
first
glanc
somewhat
surpris
given
fact
type
membran
protein
noncleav
signal
sequenc
howev
recent
studi
found
spp
complex
togeth
pdi
data
suggest
substrat
recruit
spp
occur
independ
signal
sequenc
cleavag
gener
spp
may
import
clip
integr
membran
span
select
erad
substrat
consist
view
misfold
region
integr
membran
protein
associ
spp
differ
deserv
mention
ubiquitin
mhci
attribut
mammalian
ligas
comparison
polyubiquitin
mhci
appear
facilit
howev
recent
studi
demonstr
contribut
physiolog
regul
unfold
mhci
dispens
degrad
induc
presenc
togeth
discoveri
help
shed
light
molecular
detail
underli
variou
facet
erad
pathway
anoth
exampl
erad
pathway
coopt
viru
provid
human
immunodefici
viru
hiv
downregul
sever
aspect
host
immun
includ
function
hiv
spread
transmiss
bodi
fluid
result
gradual
decreas
cell
ultim
progress
acquir
immun
defici
syndrom
aid
patient
tcell
count
drop
cellsmm
hivaid
reach
epidem
proport
affect
million
individu
worldwid
caus
million
death
first
glanc
effect
hiv
mhci
unlik
hcmv
sinc
mhci
clear
cell
surfac
degrad
action
hiv
protein
nef
howev
presenc
cell
surfac
primari
cell
surfac
receptor
viru
also
hinder
hiv
inhibit
viru
bud
interfer
assembl
hiv
virion
trigger
tcell
immun
respons
overcom
barrier
hiv
express
vpu
protein
vpu
first
shown
induc
rapid
degrad
prelysosom
compart
eventu
vpuinduc
degrad
demonstr
depend
function
up
interestingli
vpu
tailanchor
protein
interact
cooh
terminu
repeat
contain
protein
fbox
domain
scf
ligas
recruit
therefor
normal
scf
complex
particip
erad
consist
trick
becom
erad
substrat
recent
data
indic
downregul
vpu
also
requir
complex
coronaviru
hepat
c
viru
also
interact
erad
machineri
differ
way
discuss
coronaviurs
cov
rna
virus
infect
mammal
includ
human
result
respiratori
infect
ie
sever
acut
respiratori
syndrom
sar
recent
shown
cov
replic
occur
viral
induc
membran
compart
enrich
import
concentr
noner
compart
unknown
among
possibl
data
suggest
need
downregul
erad
effici
cov
replic
line
possibl
hepat
c
viru
hcv
replic
recent
link
erad
pathway
specif
ubiquitin
hcv
protein
increas
edem
edem
overexpress
viral
replic
increas
treatment
sirna
evidenc
previou
section
tabl
erad
pathway
implic
underli
mechan
sever
diseas
mani
factor
facilit
erad
substrat
select
degrad
divers
mechan
differ
substrat
may
destroy
treatment
eradrel
diseas
simpl
task
addit
therapeut
treatment
must
take
account
proteostasi
network
within
cell
compris
factor
influenc
protein
fate
synthesi
fold
degrad
traffick
even
though
still
earli
day
erad
therapeut
grow
number
approach
explor
correct
eradlink
diseas
tabl
approach
vari
degre
success
number
reason
exampl
proteostasi
network
cell
type
specif
cell
toxic
alway
problemat
sinc
modul
erad
may
secondari
effect
upr
consequ
lead
apoptosi
addit
describ
preced
section
degrad
pathway
autophagi
may
act
complementari
erad
therefor
autophagi
may
compens
chemic
inhibit
erad
pathway
section
discuss
select
exampl
recent
therapeut
strategi
appli
cystic
fibrosi
lysosom
storag
diseas
defici
famili
transthyretin
amyloid
diseas
fold
traffick
defect
rescu
incub
cell
lower
temperatur
see
sect
iia
destruct
diseasecaus
protein
appear
temperaturesensit
process
consist
fact
temperaturedepend
aggreg
wildtyp
cftr
even
observ
vitro
unfortun
low
temperatur
incub
affect
tissu
cf
viabl
therapeut
option
howev
data
suggest
modul
kinet
andor
thermodynam
aspect
fold
problem
associ
may
suffici
keep
protein
select
erad
obviou
approach
reduc
degrad
therebi
allow
protein
time
perhap
better
environ
fold
inhibit
proteasom
common
proteasom
inhibitor
use
cbzleuleuleucin
alln
acetylleuleunorleucin
lactacystin
natur
product
isol
fungu
ref
refin
proteasom
inhibitor
current
use
clinic
shown
efficaci
treatment
latestag
multipl
myeloma
compound
act
pseudosubstr
proteasom
inhibit
chymotrypticlik
activ
chymotrypticand
trypticlik
activ
case
lactacystin
ref
unfortun
proteasom
inhibit
alln
lactacystin
shift
wildtyp
cftr
solubl
form
detergentinsolubl
form
result
suggest
strategi
augment
fold
traffick
must
rescu
immatur
protein
commit
degrad
sinc
pool
aggregationpron
ubiquitin
provid
aid
endogen
chaperoneassist
fold
machineri
cell
consid
attract
altern
strategi
rescu
conform
challeng
diseasecaus
protein
one
mean
achiev
outcom
via
administr
chemic
chaperon
chemic
chaperon
first
defin
osmolyt
provid
favor
milieu
protein
fold
often
simpli
increas
strength
intramolecular
hydrophob
bond
buri
within
protein
chemic
chaperon
may
also
global
affect
cellular
proteostasi
network
thu
lead
favor
foldingtraffick
environ
chemic
chaperon
directli
bind
misfold
protein
term
pharmacolog
chaperon
compound
lower
protein
free
energi
state
may
help
protein
fold
escap
erad
andor
limit
aggreg
one
chemic
chaperon
examin
curcumin
curcumin
compon
turmer
deriv
plant
curcuma
longa
curcumin
someth
panacea
studi
treatment
diseas
cancer
inflammatori
bowel
diseas
result
vitro
effect
antiinflammatori
antioxid
proapoptot
anticanc
agent
initi
report
indic
curcumin
abl
rescu
traffick
defect
diseaserel
phenotyp
cf
mous
model
howev
inabl
reproduc
result
cast
doubt
curcumin
efficaci
cf
find
preclud
use
curcumin
treat
cf
compound
may
function
differ
step
cftr
biogenesi
work
effect
cftr
mutant
success
attempt
chemic
correct
achiev
outcom
highthroughput
screen
small
molecul
increas
activ
cell
surfac
one
case
led
isol
bisaminomethylbithiazol
deriv
although
mechan
action
compound
unknown
evid
bind
directli
cftr
recent
result
suggest
rescu
repair
fold
defect
anoth
corrector
isol
highthroughput
screen
may
bind
directli
cftr
combin
data
consist
evid
mutat
disrupt
interact
anoth
compound
rescu
gate
defect
less
common
cftr
mutant
lead
diseas
like
potenti
also
bind
directli
cftr
increas
channel
open
probabl
overal
continu
interest
perform
function
screen
small
molecul
modul
end
best
therapeut
outcom
may
combin
applic
drug
restor
foldingtraffick
defect
associ
protein
well
reduc
channel
activ
chemic
chaperon
also
use
treat
lysosom
storag
diseas
lsd
gaucher
diseas
gd
gd
result
defici
glucocerebrosidas
gc
lysosom
enzym
normal
break
glycosphingolipid
glucosylceramid
inabl
metabol
glucosylceramid
affect
mani
organ
result
hepatomegali
splenomegali
anemia
thrombocytopenia
bone
lesion
case
central
nervou
system
cn
defici
allel
variant
caus
gd
link
erad
includ
enzym
replac
therapi
success
lsd
strategi
ineffect
gd
presum
due
poor
target
exogen
enzym
macrophag
problem
partial
overcom
develop
tag
version
gc
recogn
macrophag
receptor
howev
modifi
enzym
ineffect
patient
cn
symptom
due
inabl
cross
bloodbrain
barrier
reduc
temperatur
also
appear
rescu
mutant
sever
chemic
chaperon
examin
increas
fold
traffick
effici
gc
variant
bind
gc
activ
site
pseudosubstr
unfortun
one
common
gc
mutat
larg
unrespons
chemic
chaperon
mutat
activ
site
circumv
special
problem
associ
proteasom
inhibitor
proteostasi
regul
examin
proteostasi
regul
celastrol
use
tradit
chines
medicin
induc
heat
shock
respons
upr
surprisingli
celastrol
repair
mutant
gc
lactacystin
insuffici
rescu
spite
fact
measur
proteasom
inhibit
lactacystin
indistinguish
explan
differ
may
stem
find
celastrol
alter
express
gene
suggest
proteostat
network
affect
among
gene
sever
factor
regul
heat
shock
respons
upr
latter
requir
effect
celastrol
notabl
upon
treatment
celastrol
gc
mutant
becam
recept
treatment
chemic
chaperon
combin
treatment
result
synergist
rescu
studi
highlight
import
consid
offtarget
potenti
benefici
effect
compound
observ
accumul
glucosylceramid
note
increas
calcium
efflux
er
calcium
import
cofactor
compon
er
fold
machineri
see
increas
efflux
hypothes
impair
er
fold
capac
inde
alter
er
calcium
level
inhibit
efflux
overexpress
serca
increas
er
calcium
increas
process
activ
gc
addit
note
calcium
modul
combin
proteostasi
modul
yield
synergist
rescu
studi
demonstr
delic
natur
er
fold
environ
reinforc
benefit
combin
therapeut
approach
anoth
compound
known
offtarget
desir
effect
evid
pba
pba
fdaapprov
drug
treatment
urea
cycl
disord
due
abil
function
nitrogen
scaveng
pba
also
explor
treatment
sickl
cell
anemia
variou
malign
thu
someth
surpris
pba
administr
led
measur
rescu
sever
differ
cell
type
includ
patientderiv
epitheli
cell
clinic
trial
examin
use
pba
treat
cf
partial
rescu
cftr
activ
nasal
airway
epithelium
observ
support
continu
research
mechan
action
compound
fact
proteom
analysi
outcom
pba
treatment
reveal
among
chang
increas
bip
downregul
constitut
express
subunit
proteasom
thu
pba
may
exert
desir
effect
sever
key
player
protein
fold
erad
pathway
effect
like
mediat
abil
pba
inhibit
histon
deacetylas
hdac
histon
acetyl
deacetyl
import
regul
gene
express
second
fdaapprov
drug
suberoylanilid
hydroxam
acid
saha
also
hdac
inhibitor
current
use
treat
cutan
tcell
lymphoma
clinic
trial
treatment
form
lymphoma
saha
recent
shown
rescu
channel
activ
wildtyp
level
primari
airway
epitheli
cell
silenc
specif
hdac
led
identif
key
mediat
rescu
perhap
surprisingli
silenc
broadli
alter
transcript
profil
epitheli
cell
influenc
level
mani
gene
implic
cftr
fold
traffick
pleiotrop
effect
hdac
inhibitor
like
respons
effect
amelior
diseas
phenotyp
associ
eradtarget
protein
includ
atz
pba
increas
secret
atz
patientderiv
fibroblast
cell
express
atz
mice
engin
produc
human
atz
unfortun
pba
ineffect
clinic
trial
aim
increas
serum
level
like
due
difficulti
deliv
optim
dose
affect
tissu
howev
anoth
fdaapprov
drug
carbamazepin
cbz
examin
model
atzassoci
liver
diseas
cbz
use
treat
epilepsi
applic
mood
stabil
effect
inositol
effect
ip
level
cbz
also
enhanc
autophagi
clearanc
polyq
htt
aggreg
recent
cbz
shown
enhanc
degrad
solubl
insolubl
atz
mous
model
data
make
cbz
attract
candid
treat
atassoci
liver
diseas
last
exampl
discuss
one
rare
case
knowledg
protein
structur
led
design
effect
therapeut
use
clinic
transthyretin
ttr
secret
protein
function
tetram
transport
thyroid
hormon
retinolbind
protein
bloodstream
certain
diseasecaus
variant
ttr
secret
ineffici
retain
er
degrad
erad
might
expect
variant
bind
bip
much
greater
extent
wildtyp
ttr
variant
result
diseas
eradindepend
mechan
unstabl
ttr
variant
escap
erad
form
serum
amyloid
fibril
lead
cardiomyopathi
famili
amyloid
polyneuropathi
cn
amyloidosi
basi
extens
biophys
studi
ttr
amyloidosi
shown
aris
due
kinet
destabil
secret
ttr
tetram
monom
form
fibril
therefor
molecul
stabil
tetram
therapeut
potenti
xray
crystallographi
use
determin
key
featur
amyloid
inhibitor
bind
ttr
comput
analysi
guid
design
potent
specif
small
molecul
inhibitor
ttr
amyloidosi
refin
led
discoveri
halogen
benzoxazol
compound
bound
tightli
ttr
prevent
fibril
format
compound
refer
tafimidi
current
use
treat
famili
transthyretin
amyloid
diseas
purpos
review
highlight
key
factor
direct
erad
substrat
degrad
provid
select
exampl
number
uniqu
way
erad
impact
human
physiolog
diseas
specif
detail
inclus
list
provid
tabl
howev
quit
awar
tabl
incomplet
futur
mani
diseaseassoci
erad
substrat
ad
case
data
link
particular
diseaseassoci
protein
erad
pathway
definit
suggest
mani
protein
loos
associ
variou
aspect
er
qualiti
control
resid
er
proteasomedepend
degrad
studi
hope
work
lead
indepth
investig
potenti
connect
erad
stimul
futur
research
effort
given
nearli
infinit
number
conform
secret
protein
adopt
especi
possibl
mutant
form
consid
surpris
list
alreadi
rel
long
suspect
tabl
grow
addit
secret
protein
character
illcharacter
gene
encod
secret
protein
better
defin
also
hope
work
rais
import
question
current
futur
research
effort
best
direct
treat
condit
era
person
genom
care
must
taken
accur
defin
underli
effect
diseasecaus
mutat
result
protein
misfold
promis
therapeut
examin
effect
varieti
diseas
model
secondari
effect
erad
pathway
need
examin
nascent
secretori
protein
emerg
ribosom
exit
tunnel
present
hydrophob
signal
sequenc
recogn
signal
recognit
particl
srp
bind
srp
signal
sequenc
slow
translat
target
ribosomenasc
chain
complex
er
membran
via
interact
dimer
srp
receptor
follow
releas
srp
recycl
translat
resum
nascent
solubl
protein
transloc
er
lumen
integr
membran
protein
b
incorpor
membran
transloc
complex
solubl
protein
membran
protein
hydrophob
signal
sequenc
cleav
er
local
signal
peptidas
complex
commonli
lysin
residu
client
protein
via
ubiquitin
ligas
ubiquitin
er
membran
occur
via
cytoplasm
erloc
ligas
shown
retrotransloc
polytop
membran
protein
pictur
retrotransloc
may
occur
remov
protein
channel
retrotranslocon
andor
remov
protein
surround
membran
pictur
either
case
retrotransloc
almost
alway
depend
complex
includ
interact
ubiquitin
misfold
region
substrat
provid
mechan
forc
via
atp
hydrolysi
substrat
remov
degrad
follow
retrotransloc
misfold
protein
usher
proteasom
must
kept
solubl
prevent
aggreg
nglycan
clip
nglycans
pictur
ubiquitin
moieti
remov
deubiquitin
enzym
either
cytosol
proteasom
cap
proteasom
contain
three
peptidas
activ
trypsinlik
chymotrypsinlik
caspaselik
cleav
protein
short
peptid
fragment
